FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q1 2018. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $2,799,000 | -9.2% | 920,796 | -28.9% | 0.90% | +21.2% |
| Q2 2019 | $3,084,000 | -36.5% | 1,295,669 | 0.0% | 0.74% | -43.3% |
| Q1 2019 | $4,859,000 | +17.5% | 1,295,669 | +12.5% | 1.31% | -12.9% |
| Q4 2018 | $4,134,000 | -6.3% | 1,151,510 | +49.5% | 1.51% | -0.5% |
| Q3 2018 | $4,412,000 | +459.2% | 770,000 | +486.9% | 1.51% | +240.2% |
| Q4 2017 | $789,000 | +2.1% | 131,200 | -5.7% | 0.44% | +11.0% |
| Q3 2017 | $773,000 | +19.7% | 139,200 | 0.0% | 0.40% | +30.6% |
| Q2 2017 | $646,000 | -74.9% | 139,200 | -65.7% | 0.31% | -76.7% |
| Q2 2016 | $2,574,000 | -31.1% | 405,374 | -29.2% | 1.32% | -3.8% |
| Q1 2016 | $3,734,000 | +10.7% | 572,628 | +37.7% | 1.37% | -8.5% |
| Q4 2015 | $3,374,000 | +36.9% | 415,972 | +23.7% | 1.49% | -11.6% |
| Q3 2015 | $2,465,000 | +49.1% | 336,286 | +108.5% | 1.69% | +106.9% |
| Q2 2015 | $1,653,000 | – | 161,286 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |